Relevant bibliographies by topics / Cannabinoids

Academic literature on the topic 'Cannabinoids'

Author: Grafiati
Published: 4 June 2021
Last updated: 27 July 2024

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Cannabinoids.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Cannabinoids"

1

Thomas, Fabian Johannes, and Oliver Kayser. "Minor Cannabinoids of Cannabis sativa L." Journal of Medical Science 88, no. 3 (October 1, 2019): 141–49. http://dx.doi.org/10.20883/jms.367.

Full text
Abstract:
Cannabinoids from Cannabis sativa L. play an important role as natural products in clinics. The major cannabinoids compromise tetrahydrocannabinolic acid (THCA) and cannabidiolic acid (CBDA) and its decarboxylated analogs. In this review, we focus on often neglected minor cannabinoids and discuss biosynthetic and chemical degradation routes to other neglected cannabinoids in Cannabis sativa starting from THCA, CBDA and cannabichromenic acid (CBCA). Based on the literature, patents and scientific reports, essential routes for the chemical modification of cannabinoids are discussed to explain chemical diversity chemical conversion and degradation by UV light, as well as temperature and pH leading to the formation of structurally unusual cannabinoids in planta called as minor cannabinoids. Based on known bioorganic reaction schemes and organic chemistry, principles for minor cannabinoid formation like [2+2] cycloaddition, Markonov condensation, radical introduction, or aromatization are discussed. Finally, the non-aqueous environment in Cannabis sativa trichomes is analyzed to clarify their role of a miniaturized bioreactors the light-induced conversion in a non-aqueous enviroment. The overall objective is to bridge from metabolic profiling via cannabinomics to structural and chemical diversity that allows the definition of patterns with consequences also to pharmacology and plant breeding.
APA, Harvard, Vancouver, ISO, and other styles
2

Radwan, Mohamed M., Suman Chandra, Shahbaz Gul, and Mahmoud A. ElSohly. "Cannabinoids, Phenolics, Terpenes and Alkaloids of Cannabis." Molecules 26, no. 9 (May 8, 2021): 2774. http://dx.doi.org/10.3390/molecules26092774.

Full text
Abstract:
Cannabis sativa is one of the oldest medicinal plants in the world. It was introduced into western medicine during the early 19th century. It contains a complex mixture of secondary metabolites, including cannabinoids and non-cannabinoid-type constituents. More than 500 compounds have been reported from C. sativa, of which 125 cannabinoids have been isolated and/or identified as cannabinoids. Cannabinoids are C21 terpeno-phenolic compounds specific to Cannabis. The non-cannabinoid constituents include: non-cannabinoid phenols, flavonoids, terpenes, alkaloids and others. This review discusses the chemistry of the cannabinoids and major non-cannabinoid constituents (terpenes, non-cannabinoid phenolics, and alkaloids) with special emphasis on their chemical structures, methods of isolation, and identification.
APA, Harvard, Vancouver, ISO, and other styles
3

Walker, J. Michael, Nicole M. Strangman, and Susan M. Huang. "Cannabinoids and Pain." Pain Research and Management 6, no. 2 (2001): 74–79. http://dx.doi.org/10.1155/2001/413641.

Full text
Abstract:
Cannabinoids have been used to treat pain for many centuries. However, only during the past several decades have rigorous scientific methods been applied to understand the mechanisms of cannabinoid action. Cannabinoid receptors were discovered in the late 1980s and have been found to mediate the effects of cannabinoids on the nervous system. Several endocannabinoids were subsequently identified. Many studies of cannabinoid analgesia in animals during the past century showed that cannabinoids block all types of pain studied. These effects were found to be due to the suppression of spinal and thalamic nociceptive neurons, independent of any actions on the motor systems. Spinal, supraspinal and peripheral sites of cannabinoid analgesia have been identified. Endocannabinoids are released upon electrical stimulation of the periaqueductal gray, and in response to inflammation in the extremities. These observations and others thus suggest that a natural function of cannabinoid receptors and their endogenous ligands is to regulate pain sensitivity. The therapeutic potential of cannabinoids remains an important topic for future investigations, with previous work suggesting utility in clinical studies of cancer and surgical pain. New modes of delivery and/or new compounds lacking the psychotropic properties of the standard cannabinoid ligands offer promise for cannabinoid therapeutics for pain.
APA, Harvard, Vancouver, ISO, and other styles
4

Voicu, Victor, Felix-Mircea Brehar, Corneliu Toader, Razvan-Adrian Covache-Busuioc, Antonio Daniel Corlatescu, Andrei Bordeianu, Horia Petre Costin, Bogdan-Gabriel Bratu, Luca-Andrei Glavan, and Alexandru Vlad Ciurea. "Cannabinoids in Medicine: A Multifaceted Exploration of Types, Therapeutic Applications, and Emerging Opportunities in Neurodegenerative Diseases and Cancer Therapy." Biomolecules 13, no. 9 (September 14, 2023): 1388. http://dx.doi.org/10.3390/biom13091388.

Full text
Abstract:
In this review article, we embark on a thorough exploration of cannabinoids, compounds that have garnered considerable attention for their potential therapeutic applications. Initially, this article delves into the fundamental background of cannabinoids, emphasizing the role of endogenous cannabinoids in the human body and outlining their significance in studying neurodegenerative diseases and cancer. Building on this foundation, this article categorizes cannabinoids into three main types: phytocannabinoids (plant-derived cannabinoids), endocannabinoids (naturally occurring in the body), and synthetic cannabinoids (laboratory-produced cannabinoids). The intricate mechanisms through which these compounds interact with cannabinoid receptors and signaling pathways are elucidated. A comprehensive overview of cannabinoid pharmacology follows, highlighting their absorption, distribution, metabolism, and excretion, as well as their pharmacokinetic and pharmacodynamic properties. Special emphasis is placed on the role of cannabinoids in neurodegenerative diseases, showcasing their potential benefits in conditions such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, and multiple sclerosis. The potential antitumor properties of cannabinoids are also investigated, exploring their potential therapeutic applications in cancer treatment and the mechanisms underlying their anticancer effects. Clinical aspects are thoroughly discussed, from the viability of cannabinoids as therapeutic agents to current clinical trials, safety considerations, and the adverse effects observed. This review culminates in a discussion of promising future research avenues and the broader implications for cannabinoid-based therapies, concluding with a reflection on the immense potential of cannabinoids in modern medicine.
APA, Harvard, Vancouver, ISO, and other styles
5

Huffman, J. W., and J. A. H. Lainton. "Recent Developments Cannabinoids in the Medicinal Chemistry of Cannabinoids." Current Medicinal Chemistry 3, no. 2 (April 1996): 101–16. http://dx.doi.org/10.2174/092986730302220302094839.

Full text
Abstract:
Abstract: As a result of the recognition of a cannabinoid receptor, the isolation of the first endogenous cannabinoid and, more recently, the significant discovery of a cannabinoid antagonist, there has been a resurgence of interest in the medicinal chemistry of cannabinoids. This has included inter alia investigations into the effects of side chain substitution and overall molecular geometry on the biological activity of traditional cannabi­ noids, which are partially reduced dibenzopyrans, as well as the design and synthesis of a variety of non-traditional cannabinoids. These compounds include indole and pyrrole derivatives, which are agonists, a diarylpyrazole, which is the first cannabinoid antagonist, and various amides of arachidonic acid. The latter compounds are patterned on anandamide (arachidonic acid ethanolamide), the first endogenous cannabinoid isolated from mammalian brain tissue. Modeling studies of the cannabinoid receptor are beginning to provide some insight into the interaction of various agonists with the receptor. This article will review recent developments in the medicinal chemistry of cannabinoids with an emphasis on work reported since 1992.
APA, Harvard, Vancouver, ISO, and other styles
6

Sun, Yan, and Andy Bennett. "Cannabinoids: A New Group of Agonists of PPARs." PPAR Research 2007 (2007): 1–7. http://dx.doi.org/10.1155/2007/23513.

Full text
Abstract:
Cannabinoids have been used medicinally and recreationally for thousands of years and their effects were proposed to occur mainly via activation of the G-protein-coupled receptorCB1/CB2(cannabinoid receptor 1/2). Discovery of potent synthetic analogs of the natural cannabinoids as clinically useful drugs is the sustained aim of cannabinoid research. This demands that these new compounds be free of the psychotropic effects that connected with the recreational use of cannabinoids. In preclinical studies cannabinoids displayed many of the characteristics of nonsteroidal anti-inflammatory drugs (NSAIDs) and it seems to be free of unwanted side effects. An increasing number of therapeutic actions of cannabinoid are being reported that do not appear to be mediated by eitherCB1orCB2, and recently nuclear receptor superfamily PPARs (peroxisome-proliferator-activated receptors) have been suggested as the target of certain cannabinoids. This review summarizes the evidence for cannabinoid activation on PPARs and possible associated remedial potentials.
APA, Harvard, Vancouver, ISO, and other styles
7

Sun, Y., S. P. H. Alexander, D. A. Kendall, and A. J. Bennett. "Cannabinoids and PPARα signalling." Biochemical Society Transactions 34, no. 6 (October 25, 2006): 1095–97. http://dx.doi.org/10.1042/bst0341095.

Full text
Abstract:
Cannabinoids have been shown to possess anti-inflammatory and neuroprotective properties, which were proposed to occur mainly via activation of the G-protein-coupled receptor CB1 (cannabinoid receptor 1). Recently, certain cannabinoids have been reported to be ligands for members of the nuclear receptor transcription factor superfamily known as PPARs (peroxisome-proliferator-activated receptors). This review summarizes the evidence for cannabinoid activation of PPARs and identifies a new intracellular target for cannabinoids as therapeutic agents for neuroprotective treatment.
APA, Harvard, Vancouver, ISO, and other styles
8

Xiong, Wei, Tanxing Cui, Kejun Cheng, Fei Yang, Shao-Rui Chen, Dan Willenbring, Yun Guan, et al. "Cannabinoids suppress inflammatory and neuropathic pain by targeting α3 glycine receptors." Journal of Experimental Medicine 209, no. 6 (May 14, 2012): 1121–34. http://dx.doi.org/10.1084/jem.20120242.

Full text
Abstract:
Certain types of nonpsychoactive cannabinoids can potentiate glycine receptors (GlyRs), an important target for nociceptive regulation at the spinal level. However, little is known about the potential and mechanism of glycinergic cannabinoids for chronic pain treatment. We report that systemic and intrathecal administration of cannabidiol (CBD), a major nonpsychoactive component of marijuana, and its modified derivatives significantly suppress chronic inflammatory and neuropathic pain without causing apparent analgesic tolerance in rodents. The cannabinoids significantly potentiate glycine currents in dorsal horn neurons in rat spinal cord slices. The analgesic potency of 11 structurally similar cannabinoids is positively correlated with cannabinoid potentiation of the α3 GlyRs. In contrast, the cannabinoid analgesia is neither correlated with their binding affinity for CB1 and CB2 receptors nor with their psychoactive side effects. NMR analysis reveals a direct interaction between CBD and S296 in the third transmembrane domain of purified α3 GlyR. The cannabinoid-induced analgesic effect is absent in mice lacking the α3 GlyRs. Our findings suggest that the α3 GlyRs mediate glycinergic cannabinoid-induced suppression of chronic pain. These cannabinoids may represent a novel class of therapeutic agents for the treatment of chronic pain and other diseases involving GlyR dysfunction.
APA, Harvard, Vancouver, ISO, and other styles
9

Irving, Andrew J., Mark G. Rae, and Angela A. Coutts. "Cannabinoids on the Brain." Scientific World JOURNAL 2 (2002): 632–48. http://dx.doi.org/10.1100/tsw.2002.139.

Full text
Abstract:
Cannabis has a long history of consumption both for recreational and medicinal uses. Recently there have been significant advances in our understanding of how cannabis and related compounds (cannabinoids) affect the brain and this review addresses the current state of knowledge of these effects. Cannabinoids act primarily via two types of receptor, CB1and CB2, with CB1receptors mediating most of the central actions of cannabinoids. The presence of a new type of brain cannabinoid receptor is also indicated. Important advances have been made in our understanding of cannabinoid receptor signaling pathways, their modulation of synaptic transmission and plasticity, the cellular targets of cannabinoids in different central nervous system (CNS) regions and, in particular, the role of the endogenous brain cannabinoid (endocannabinoid) system. Cannabinoids have widespread actions in the brain: in the hippocampus they influence learning and memory; in the basal ganglia they modulate locomotor activity and reward pathways; in the hypothalamus they have a role in the control of appetite. Cannabinoids may also be protective against neurodegeneration and brain damage and exhibit anticonvulsant activity. Some of the analgesic effects of cannabinoids also appear to involve sites within the brain. These advances in our understanding of the actions of cannabinoids and the brain endocannabinoid system have led to important new insights into neuronal function which are likely to result in the development of new therapeutic strategies for the treatment of a number of key CNS disorders.
APA, Harvard, Vancouver, ISO, and other styles
10

Sharon, Nitzan, Ludmila Yarmolinsky, Boris Khalfin, Sigal Fleisher-Berkovich, and Shimon Ben-Shabat. "Cannabinoids’ Role in Modulating Central and Peripheral Immunity in Neurodegenerative Diseases." International Journal of Molecular Sciences 25, no. 12 (June 10, 2024): 6402. http://dx.doi.org/10.3390/ijms25126402.

Full text
Abstract:
Cannabinoids (the endocannabinoids, the synthetic cannabinoids, and the phytocannabinoids) are well known for their various pharmacological properties, including neuroprotective and anti-inflammatory features, which are fundamentally important for the treatment of neurodegenerative diseases. The aging of the global population is causing an increase in these diseases that require the development of effective drugs to be even more urgent. Taking into account the unavailability of effective drugs for neurodegenerative diseases, it seems appropriate to consider the role of cannabinoids in the treatment of these diseases. To our knowledge, few reviews are devoted to cannabinoids’ impact on modulating central and peripheral immunity in neurodegenerative diseases. The objective of this review is to provide the best possible information about the cannabinoid receptors and immuno-modulation features, peripheral immune modulation by cannabinoids, cannabinoid-based therapies for the treatment of neurological disorders, and the future development prospects of making cannabinoids versatile tools in the pursuit of effective drugs.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Cannabinoids"

1

Goonawardena, Anushka V. "Cannabinoid effects on hippocampal neurophysiology and mnemonic processing." Thesis, Available from the University of Aberdeen Library and Historic Collections Digital Resources. Restricted: no access until Mar. 17, 2011, 2008. http://digitool.abdn.ac.uk:80/webclient/DeliveryManager?application=DIGITOOL-3&owner=resourcediscovery&custom_att_2=simple_viewer&pid=26047.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Whyte, Lauren Sarah. "Molecular pharmocology of cannabinoids and the novel cannabinoid receptor GPR55 in bone." Thesis, University of Aberdeen, 2009. http://digitool.abdn.ac.uk:80/webclient/DeliveryManager?pid=103940.

Full text
Abstract:
Given the recent finding that the cannabinoid receptors CB1 and CB2 affect bone metabolism, we examined the role of GPR55 in bone biology. GPR55 was expressed in human and mouse osteoclasts and osteoblasts; expression was higher in human osteoclasts than in macrophage progenitors. Although the GPR55 agonists O-1602 and LPI inhibited mouse osteoclast formation in vitro, these ligands stimulated mouse and human osteoclast polarisation and resorption in vitro and caused activation of Rho and ERK1/2. These stimulatory effects on osteoclast function were attenuated in osteoclasts generated from GPR55-/- macrophages and by the GPR55 antagonist cannabidiol (CBD). Furthermore, treatment of mice with this non-psychoactive constituent of cannabis significantly reduced bone resorption in vivo. Consistent with the ability of GPR55 to suppress osteoclast formation but stimulate osteoclast function, histomorphometric and microcomputed tomographic analysis of the long bones from male GPR55-/- mice revealed increased numbers of morphologically-inactive osteoblasts, but a significant increase in the volume and thickness of trabecular bone and the presence of unresorbed cartilage. These data reveal a hitherto unrecognised role of GPR55 in bone physiology by regulating osteoclast number and function. In addition, this study also brings to light a newly identified effect of both the endogenous ligand, LPI , on osteoclasts and of the cannabis constituent, CBD, on osteoclasts and bone turnover in vivo. These results suggest that blocking GPR55 with small molecules similar to CBD may be beneficial in bone diseases associated with increased osteoclast activity such as osteoporosis.
APA, Harvard, Vancouver, ISO, and other styles
3

Li, Yan. "THE ROLE OF CANNABINOIDS AND CANNABINOID RECEPTORS IN ENTERIC NEURONAL SURVIVAL." VCU Scholars Compass, 2009. http://scholarscompass.vcu.edu/etd/1947.

Full text
Abstract:
The Endocannabinoid system has been found in the gastrointestinal tract, where it plays an important role in gut under both physiological and pathological conditions. Although the major effects of cannabinoids in the gut are mediated through effects on enteric neurons, the role of cannabinoids in the enteric nervous system is poorly understood. In the present study, we have used the primary cultures of myenteric ganglia and a newly developed fetal enteric neuronal cell line to identify whether the endocannabinoid, anandamide, affects ganglionic and neuronal survival and the pathways involved. Anandamide had a biphasic effect on ganglionic survival, increasing survival at low concentrations (1nM-0.1uM) and decreasing survival at high concentrations (1-10uM). Maximal survival (68% increase in number of ganglia surviving) occurred at 0.1uM and the ED50 was 3nM. This effect on promoting survival was inhibited by the CB1 antagonist AM251 (1uM) and by AraC (10uM), but not the CB2 antagonist AM630 (1uM). AM630 (1uM) significantly blocked the decreased survival induced by high concentration anandamide (10uM). The enteric glia was involved in anandamide-induced ganglion survival. Anandamide had no effect on the number of neurons/ganglion in the presence of enteric glia, but decreased the number of neurons/ganglion by 15-20% in absence of enteric glia. This effect was partially reversed by CB1 antagonist, AM251 (1uM) (20%-145% at 1nM-10uM) and by CB2 antagonist AM630 (1uM) (40%-185% at 1nM-10uM). In the fetal enteric neural cell line (IM-FEN), anandamide decreased enteric neuronal survival in a concentration-dependent manner at both 39 and 33 degree (11-45% and 10-22%decrease in survival at 1nM-10uM, respectively). Coculture of astrocytes with the enteric neuronal cells was not able to reverse anandamide-mediated neuronal death. Immunocytochemistry and western blot confirmed that the presence of both CB1 and CB2 receptors in enteric neurons (primary cultures and IM-FEN) and glia (primary cultures). In addition, the PLC-beta inhibitor U73122 (1uM) inhibited anandamide induced ganglia survival significantly. Anandamide also induced increased expression of phospho-P44/42MAPK (13-48% at 1nM-10uM) and phospho-AKT (1-28% at 1 nM-10uM) in IM-FEN. We conclude that anandamide has a differential effect on survival of enteric ganglia and neurons. It promotes ganglionic and neuronal survival by CB1 receptors in the presence of glia and this involves the PLC-beta pathway. Conversely, anandamide promotes neuron death in absence of glia as a result of effects on both the MAPK and PI-3K/AKT pathways. Since the endocannabinoid system is upregulated in inflammatory bowel diseases, these effects may play a role in the pathogenesis of the response to inflammation as well as the recovery and reinnervation of the gut following the acute phase of inflammation. The further significance of this work could contribute to developing new therapeutic methods for treatment of inflammatory bowel disease and related symptoms in clinic practice.
APA, Harvard, Vancouver, ISO, and other styles
4

Firth, D. F. "Cannabinoids and cembranoids." Thesis, University of Nottingham, 1987. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.380140.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Habayeb, Osama. "Cannabinoids and reproduction." Thesis, University of Leicester, 2009. http://hdl.handle.net/2381/29866.

Full text
Abstract:
The success of implantation depends on the synchronous development of the embryo and the endometrium. This process is recognised to be regulated by the endocannabinoid system, the most widely studied of which is anandamide.;The first part of this study was the development of a robust assay to measure anandamide in human plasma. The assay was then applied to measure anandamide concentrations during the menstrual cycle, pregnancy, labour and in a group of women presenting with threatened miscarriage. The mean plasma anandamide levels in the follicular phase were 1.68 nM compared to 0.87 in the luteal phase. In pregnancy, the mean levels in the first trimester were 0.89 nM and 0.44 in both the second and third trimesters. At term, the mean levels were 0.68 in the non-labour group and to 2.5 nM in labour. In the threatened miscarriage group, anandamide levels >2.0 nM were predictive of subsequent miscarriage with sensitivity of 100%, specificity of 94.4%, negative predictive value of 100% and positive predictive value of 81.8%.;Finally, to try and identify potential targets of anandamide action, the expression of the cannabinoid receptors (CB1 & CB2) and the enzyme FAAH was studied in first trimester placentas. All proteins studied were present in the tissues examined with the expression of the CB1 diminishing after 9 weeks and FAAH disappearing by 11 weeks gestation. Similarly, anandamide inhibited the growth of BeWo cells in culture. Taken together, these findings suggest that anandamide plays a role in the maintenance of early pregnancy.
APA, Harvard, Vancouver, ISO, and other styles
6

Nilsson, Olov. "Cannabinoids as neuroprotective agents : a mechanistic study." Doctoral thesis, Umeå : Umeå universitet, 2006. http://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-873.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Brown, Nigel Kenneth. "Metabolism of the cannabinoids." Thesis, University of Oxford, 1989. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.236245.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Dudasova, Anita. "Cannabinoids and bronchial airways." Thesis, University of Hertfordshire, 2009. http://hdl.handle.net/2299/3638.

Full text
Abstract:
Although there is a renewed interest in the therapeutic potential of cannabinoids, pharmacological and physiological characterisation of these promising compounds is currently not well documented in the respiratory system. The aim of this study is to increase our understanding of possible roles of cannabinoids in the airways. Apart from CB1 and CB2 receptor-mediated actions, cannabinoid compounds can also target TRPV1 receptors, ion channels or the orphan GPR55. In isolated guinea-pig bronchi, WIN55212-2 probably exerted its inhibitory effect on sensory nerves through CB2-like receptors. VIR did not act prejunctionally but its excitatory action was mediated through TRPV1 receptors. Δ9-THC activated sensory nerves presumably involving CB1 receptors. It was speculated that GPR55 might be activated by VIR and antagonized by CBD. CBD revealed multiple mechanisms of actions: it antagonized effects mediated by TRPV1 and NK2 receptors, modulated mast cell function and showed anti-allergic activity in an in vitro model of bronchial asthma. In a human bronchial epithelial cell line the functional expression of CB1 receptors could not be confirmed. Cannabinoids examined in this study were ineffective to induce signal transduction which would be linked to ion channel activity or to intracellular Ca2+ changes. Only VIR might trigger a CB1 receptor-independent signalling pathway in these cells. In conclusion, the findings presented in this thesis reflect the diversity of cannabinoid pharmacology in the airways. They show for the first time that CBD has the ability to reduce antigen-induced bronchoconstriction, indicating relevance in bronchial asthma.
APA, Harvard, Vancouver, ISO, and other styles
9

Sun, Yan. "Cannabinoids and PPARa signalling." Thesis, University of Nottingham, 2006. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.431260.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Casey, Sherelle. "Cannabinoids for Neuropathic Pain." Thesis, University of Sydney, 2020. https://hdl.handle.net/2123/24007.

Full text
Abstract:
Neuropathic pain is a severe chronic syndrome and is poorly served by current pharmacotherapeutics. There is some evidence that the cannabis constituents tetrahydrocannabinol (THC), cannabidiol (CBD), and their combination relieves neuropathic pain. However, there is little to no animal evidence for their effectiveness and side effects in neuropathic pain models. In this thesis, a systematic analysis of THC and CBD was performed in a mouse neuropathic pain model. Systemic subcutaneous and oral THC had high anti-allodynic efficacy, but was accompanied by side effects. By contrast, CBD had lower anti-allodynic efficacy, but lacked side effects. Isobolographic analysis demonstrated synergistic analgesia for combination THC and CBD for subcutaneous but not oral administration. Thus, combination THC:CBD had a high therapeutic window when delivered subcutaneously but not orally. Finally, both THC and CBD produced high efficacy anti-allodynia without side effects administered via intrathecal or intraplantar injection. The actions of THC were mostly cannabinoid CB1 receptor mediated, while the actions of CBD were not cannabinoid receptor mediated. An in vitro electrophysiological identified potential cannabinoid targets in sensory neurons. Activity at T-type calcium currents, but not other calcium currents or tetrodotoxin-resistant sodium currents, may account for some of the anti-allodynic activity of THC and CBD. Overall, this thesis provides pre-clinical evidence that the phytocannabinoids THC and CBD alone may be useful as an adjunct therapy for treatment of neuropathic pain, and provides insight as to the ideal ratio and differing benefits and challenges of different administration routes. It also provides some insight into the cellular mechanisms of activity of these phytocannabinoids.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Cannabinoids"

1

Vincenzo, Di Marzo, ed. Cannabinoids. Georgetown, Tex: Landes Bioscience / Eurekah.com, 2004.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Di Marzo, Vincenzo, ed. Cannabinoids. Chichester, UK: John Wiley & Sons, Ltd, 2014. http://dx.doi.org/10.1002/9781118451281.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Pertwee, Roger G., ed. Cannabinoids. Berlin, Heidelberg: Springer Berlin Heidelberg, 2005. http://dx.doi.org/10.1007/b137831.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Reggio, Patricia H. The cannabinoid receptors. New York: Humana, 2009.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Reggio, Patricia H. The cannabinoid receptors. New York: Humana, 2009.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Narouze, Samer N., ed. Cannabinoids and Pain. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-69186-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Mechoulam, Raphael, ed. Cannabinoids as Therapeutics. Basel: Birkhäuser Basel, 2005. http://dx.doi.org/10.1007/3-7643-7358-x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Monti, Jaime M., S. R. Pandi-Perumal, and Eric Murillo-Rodríguez, eds. Cannabinoids and Sleep. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-61663-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Raphael, Mechoulam, ed. Cannabinoids as therapeutic agents. Boca Raton, Fla: CRC Press, 1986.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

ElSohly, Mahmoud A., ed. Marijuana and the Cannabinoids. Totowa, NJ: Humana Press, 2007. http://dx.doi.org/10.1007/978-1-59259-947-9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Cannabinoids"

1

Mechoulam, Raphael. "Looking ahead after 50 years of research on cannabinoids." In Cannabinoids, 1–15. Chichester, UK: John Wiley & Sons, Ltd, 2014. http://dx.doi.org/10.1002/9781118451281.ch1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Blume, Lawrence C., Khalil M. Eldeeb, and Allyn C. Howlett. "Cannabinoid receptor intracellular signalling: The long journey from binding sites to biological effects." In Cannabinoids, 17–52. Chichester, UK: John Wiley & Sons, Ltd, 2014. http://dx.doi.org/10.1002/9781118451281.ch2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Fezza, Filomena, and Mauro Maccarrone. "Endocannabinoid biochemistry: What do we know after 50 years?" In Cannabinoids, 53–94. Chichester, UK: John Wiley & Sons, Ltd, 2014. http://dx.doi.org/10.1002/9781118451281.ch3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Lutz, Beat. "Genetic dissection of the endocannabinoid system and how it changed our knowledge of cannabinoid pharmacology and mammalian physiology." In Cannabinoids, 95–137. Chichester, UK: John Wiley & Sons, Ltd, 2014. http://dx.doi.org/10.1002/9781118451281.ch4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Hillard, Cecilia J., Qing-song Liu, XiaoQian Liu, Bin Pan, Christopher J. Roberts, and Leyu Shi. "Cannabinoids, endocannabinoids and stress." In Cannabinoids, 139–74. Chichester, UK: John Wiley & Sons, Ltd, 2014. http://dx.doi.org/10.1002/9781118451281.ch5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Fernández-Ruiz, Javier, Mariluz Hernández, and Yolanda García-Movellán. "Cannabinoids and the brain: New hopes for new therapies." In Cannabinoids, 175–218. Chichester, UK: John Wiley & Sons, Ltd, 2014. http://dx.doi.org/10.1002/9781118451281.ch6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Caraceni, Paolo, Francesca Borrelli, Ferdinando A. Giannone, and Angelo A. Izzo. "Potential therapeutic applications of cannabinoids in gastrointestinal and liver diseases: Focus on Δ9-tetrahydrocannabinol pharmacology." In Cannabinoids, 219–60. Chichester, UK: John Wiley & Sons, Ltd, 2014. http://dx.doi.org/10.1002/9781118451281.ch7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Marzo, Vincenzo Di, and Luciano De Petrocellis. "Fifty years of ‘cannabinoid research’ and the need for a new nomenclature." In Cannabinoids, 261–89. Chichester, UK: John Wiley & Sons, Ltd, 2014. http://dx.doi.org/10.1002/9781118451281.ch8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Hoyer, Daniel, Eric P. Zorrilla, Pietro Cottone, Sarah Parylak, Micaela Morelli, Nicola Simola, Nicola Simola, et al. "Cannabinoids." In Encyclopedia of Psychopharmacology, 265. Berlin, Heidelberg: Springer Berlin Heidelberg, 2010. http://dx.doi.org/10.1007/978-3-540-68706-1_540.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Canavero, Sergio, and Vincenzo Bonicalzi. "Cannabinoids." In Central Pain Syndrome, 371–84. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-56765-5_17.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Cannabinoids"

1

Lagano, Laura. "Cannabinoids & Health." In Virtual 2020 AOCS Annual Meeting & Expo. American Oil Chemists’ Society (AOCS), 2020. http://dx.doi.org/10.21748/am20.25.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Morris, Tamara, Peter J. Winsauer, Scott Edwards, and Jessica Cucinello-Ragland. "Effects of Cannabinoids and a Cannabinoid Extract on Thermal Nociception and Conditioned Behavior." In ASPET 2023 Annual Meeting Abstracts. American Society for Pharmacology and Experimental Therapeutics, 2023. http://dx.doi.org/10.1124/jpet.122.254130.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Zirkle, Ross. "Synthetic Biology and Cannabinoids." In Virtual 2020 AOCS Annual Meeting & Expo. American Oil Chemists' Society (AOCS), 2020. http://dx.doi.org/10.21748/am20.168.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Blebea, Nicoleta Mirela, and Simona Negreș. "METHODS FOR QUANTIFICATION OF THE MAIN CANNABINOIDS IN CBD OIL." In GEOLINKS Conference Proceedings. Saima Consult Ltd, 2021. http://dx.doi.org/10.32008/geolinks2021/b1/v3/13.

Full text
Abstract:
Cannabidiol (CBD) is an alkaloid present in Cannabis sativa, together with tetrahydrocannabinol (THC) and more than 120 other substances belonging to a group of compounds named cannabinoids. Due to the continuous increased usage of CBD oils, it became necessary to be developed efficient methods for the identification of its compounds and especially for the characterization of the cannabinoids from the commercial specimens. Cannabinoids may be detected by many and different analytical methods, including immunoassays (EMIT®, Elisa, fluorescent polarization, radioimmunotest), techniques of flat chromatography: classic thin layer chromatography (TLC), optimum performance laminar chromatography (OPLC) and multiple development automatization (AMD), gas chromatography-mass spectrometry (GC-MS), high-performance liquid chromatography-mass spectrometry (HPLC-MS). Ultraviolet signal (UV) is used for the quantification of major cannabinoids and the mass spectrometer is used for the quantification of minor cannabinoids. The purpose of this study was to compare the performances of TLC, Ultra High-Performance Liquid chromatography with Photodiode Array Detection (UHPLC with PDA) and LC-MS/ MS technique for the qualitative and quantitative determination of cannabinoids in 3 commercial oils with CBD. Having in view that CBD may be found in many forms of oils, on the legal market of the internet, we believe that the development of a method for the qualitative and quantitative determination may be an interesting subject for the pharmaceutical professional persons.
APA, Harvard, Vancouver, ISO, and other styles
5

Pečan, Luka Irenej, Francisco-Righoberto Barrios, and Jeran Marko. "Cannabinoid Molecules from Cannabis Sativa L. as a Promissing Solution for Methicillin-Resistant Staphylococcus Aureus (MRSA)." In Socratic Lectures 8. University of Lubljana Press, 2023. http://dx.doi.org/10.55295/psl.2023.i15.

Full text
Abstract:
Scientists are working to develop new types of antibiotics to combat the growing problem of antibiotic resistance in bacteria. One potential source of these new drugs is the plant Cannabis sativa L., which has been used for medical purposes for centuries. The beneficial properties of this plant are mainly due to the presence of compounds called cannabinoids. Researchers are currently exploring the use of cannabinoids to treat various infections, although they are mainly known for their psychoactive effects. Some studies have shown that certain cannabinoids can be effective against harmful bacteria including those that are resistant to common antibiotics. In addition, a combination of different antibiotics has been shown to be more effective than a single antibiotic. Keywords: Cannabis sativa L.; Cannabinoids; Methicillin-resistant S. aureus (MRSA); Antibiotics; Bacteria; Biological activity
APA, Harvard, Vancouver, ISO, and other styles
6

Alkhelb, Dalal, Christos Iliopoulos-Tsoutsouva, Spyridon P. Nikas, Michael S. Malamas, Alexandros Makriyannis, and Rajeev I. I. Desai. "Effects of Cannabinoids on Fentanyl Antinociception." In ASPET 2023 Annual Meeting Abstracts. American Society for Pharmacology and Experimental Therapeutics, 2023. http://dx.doi.org/10.1124/jpet.122.264140.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Burlacu, Catalina Mercedes, Steluta Gosav, Bianca Andreea Burlacu, and Mirela Praisler. "Convolutional Neural Network Detecting Synthetic Cannabinoids." In 2021 International Conference on e-Health and Bioengineering (EHB). IEEE, 2021. http://dx.doi.org/10.1109/ehb52898.2021.9657725.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Singh, A., and M. Csete. "Acute Lung Injury Induced by Vaping Cannabinoids." In American Thoracic Society 2020 International Conference, May 15-20, 2020 - Philadelphia, PA. American Thoracic Society, 2020. http://dx.doi.org/10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a6678.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Tay, Li-Lin, and John Hulse. "Self-Assembled Plasmonic Array Sensors for Cannabinoids." In Optical Sensors. Washington, D.C.: Optica Publishing Group, 2022. http://dx.doi.org/10.1364/sensors.2022.sm4e.6.

Full text
Abstract:
Multilayered vertically aligned gold nanorod (AuNR) arrays are synthesized through a self-assembly process. Coupling of the localized surface plasmon resonances of AuNRs upon resonant excitation enables highly localized electromagnetic fields along the long axis of the AuNR when illuminated. Vertical alignment allows for the formation of larger “hot volumes” where many more analyte molecules can benefit from the field enhancement as compared to conventional SERS sensors. In this paper, we will demonstrate the use of plasmonic array sensors for the detection of cannabinoids.
APA, Harvard, Vancouver, ISO, and other styles
10

Prebihalo, Sarah, Geoffrey Dubrow, Pierluigi Delmonte, and Rahul Pawar. "Development of a method for the identification and quantification of terpenes and cannabinoids in hemp using multidimensional gas chromatography and quadrupole-orbitrap mass spectrometry." In 2022 AOCS Annual Meeting & Expo. American Oil Chemists' Society (AOCS), 2022. http://dx.doi.org/10.21748/gtan2234.

Full text
Abstract:
Since the passage of the 2018 Farm Bill, hemp-containing food products, including those marketed as dietary supplements, have proliferated in the U.S. marketplace, necessitating the development of analytical methods for the identification and quantification of cannabinoids in hemp. Reports suggesting a possible contribution of terpenes on the effects of cannabinoids further expands the demand for analytical methods that can accurately determine the terpenes profile for these products. Due to the complex composition of hemp, one-dimensional chromatographic methods may be proven to be insufficient for unmasking trace level terpenes which may play an important role in the chemical properties of hemp-materials. To address this challenge, a method combining multidimensional gas chromatography (GC×GC) and high-resolution quadrupole-orbitrap mass spectrometry has been developed. The reported method provides accurate analysis of fifty-six terpenes and nine cannabinoids, including but not limited to, CBD and D-9-THC, in various varieties of hemp plant material.
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Cannabinoids"

1

Köck, Patrick, Arndt-Lukas Klaassen, M. Meyer, J. Kindler, and M. Kaess. Cannabinoids as therapeutics in child and adolescent psychiatry. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, March 2023. http://dx.doi.org/10.37766/inplasy2023.3.0017.

Full text
Abstract:
Review question / Objective: P = Children and adolescents with psychiatric disorders; I = Cannabinoids as therapeutic product / medication; C = if randomised controlled trial, placebo; O = Evaluation of psychiatric symptoms (BDI for depression, symptom severity scales in case of ADHD or Autism Spectrum Disorders); S = Randomized controlled trials, controlled trials, case studies. Rationale: Cannabinoids especially THC and CBD have gained increasing scientific interest. Various studies have been published assessing the therapeutic applications of cannabinoids in psychiatry. Several systematic reviews have been published for application of cannabinoids in psychiatry for adults, however there is no recent systematic review assessing applications for child and adolescent psychiatry.
APA, Harvard, Vancouver, ISO, and other styles
2

Goakar, Darshana, LGK Prasad, and M. R. Rao. Cannabinoid Analysis in Humans. ImmunAG, LLP., August 2018. http://dx.doi.org/10.31013/cahwtpp112020.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Wiley, Jenny, Julie Marusich, J. W. Huffman, R. L. Balster, and Brian Thomas. Hijacking of Basic Research: The Case of Synthetic Cannabinoids. Research Triangle Park, NC: RTI Press, November 2011. http://dx.doi.org/10.3768/rtipress.2011.op.0007.1111.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Skoczinski, Pia, Franjo Grotenhermen, Bernhard Beitzke, Michael Carus, and Achim Raschka. Production of Cannabinoids via Extraction, Chemical Synthesis and Especially Biotechnology. Nova-Institut GmbH, January 2021. http://dx.doi.org/10.52548/hxld8250.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Cushing, Donish, and Bomi Joseph. Synthetic cannabinoids severely elevate amino transferase levels. Natural cannabidiol does not. Peak Health Center, July 2018. http://dx.doi.org/10.31013/2001e.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Ramos, Lauren. Therapeutic potential of cannabinoids in the management of Alzheimer's Disease and other neurodegenerative conditions. Ames (Iowa): Iowa State University, January 2019. http://dx.doi.org/10.31274/cc-20240624-1505.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Kamaruzzaman, Mohd Amir, Muhammad Hibatullah Romli, Razif Abas, Sharmili Vidyadaran, Mohamad Taufik Hidayat Baharuldin, Muhammad Luqman Nasaruddin, Vishnnumukkala Thirupathirao, et al. Impact of Endocannabinoid Mediated Glial Cells on Cognitive Function in Alzheimer’s Disease: A Systematic Review and Meta-Analysis of Animal Studies. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, August 2022. http://dx.doi.org/10.37766/inplasy2022.8.0094.

Full text
Abstract:
Review question / Objective: This review aims to review systematically, and meta-analyse published pre-clinical research about the mechanism of endocannabinoid system modulation on glial cells and their effects on cognitive function in designated Alzheimer’s Disease (AD) in the animal model. Condition being studied: Its been acknowledged that the cure of Alzheimer's disease is still vague. Current medicine is working on symptoms only but never stop the disease progression due to neuronal loss. In recent years, researches have found that cannabinoid which is derived from cannabis sativa plant and its compounds exert neuroprotective effects in vitro and in vivo. In fact, cognitive improvement has been shown in some clinical studies. Therefore, the knowledge of cannabinoids and its interaction with living physiological environment like glial cells is crucial as immunomodulation to strategize the potential target of this substance. The original articles from related study relating endocannabinoid mediated glial cell were extracted to summarize and meta-analyze its impact and possible mechanism against cognitive decline in AD.
APA, Harvard, Vancouver, ISO, and other styles
8

Arnold, Jonathon, David Allsop, Nicholas Lintzeris, and Iain McGregor. Pharmacological actions and associated therapeutic levels of phytocannabinoids Addendum 2021. The Sax Institute, January 2016. http://dx.doi.org/10.57022/ovds2305.

Full text
Abstract:
This review examined the pharmacological and possible therapeutic effects of various plant-derived cannabinoids (phytocannabinoids) in adults and children. There is reasonably good evidence of the therapeutic effects of CBD, with no evidence of THC-like intoxication. Evidence relating to potential therapeutic effects of the remaining phytocannabinoids mostly comes from preclinical studies, with little evidence of intoxication. Additional human studies are required.
APA, Harvard, Vancouver, ISO, and other styles
9

West, Abby L., Nabila Hoque, Joseph Dougherty, Shashi P. Karna, and Mark H. Griep. Conjugation of the Dark Quencher QSY 7 to Various Synthetic Cannabinoids for Use in Fluorescence-Based Detection Platforms. Fort Belvoir, VA: Defense Technical Information Center, February 2015. http://dx.doi.org/10.21236/ada613664.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Bryan Sallee, Colleen E. Characterization of Reference Material 8210:. Gaithersburg, MD: National Institute of Standards and Technology, 2024. http://dx.doi.org/10.6028/nist.sp.260-248.

Full text
Abstract:
The National Institute of Standards and Technology (NIST) Reference Material (RM) 8210 Hemp Plant delivers non certified values for cannabinoids and toxic elements in a dried ground hemp plant material to help cannabis and forensic laboratories for use as a control and research material. A unit of RM 8210 contains three sample packets (approximately 1.5 g each), each sealed with a desiccant pouch in an aluminized polyester bag. This publication documents the production, analytical methods, and computations involved in characterizing this product.
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Cannabinoids' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography